NASDAQ:IVA Inventiva (IVA) Stock Price, News & Analysis $3.14 -0.31 (-9.10%) Closing price 03:58 PM EasternExtended Trading$3.14 +0.01 (+0.29%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Inventiva Stock (NASDAQ:IVA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inventiva alerts:Sign Up Key Stats Today's Range$3.13▼$3.4450-Day Range$2.87▼$4.0352-Week Range$2.82▼$7.29Volume3.02 million shsAverage Volume1.15 million shsMarket Capitalization$749.97 millionP/E RatioN/ADividend YieldN/APrice Target$14.67Consensus RatingModerate Buy Company Overview Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders. Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028. Inventiva was founded by former Abbott Laboratories executives and became a French public limited company in 2016. Its American Depositary Shares trade on the Nasdaq Global Market under the symbol IVA, while its ordinary shares are listed on Euronext Paris. The company is led by Chief Executive Officer Andrew Obenshain, who succeeded co-founder Frédéric Cren in October 2025. AI Generated. May Contain Errors. Read More Inventiva Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreIVA MarketRank™: 2.666758166345 of 5 starsInventiva scored higher than 53% of companies evaluated by MarketBeat, and ranked 395th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingInventiva has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialInventiva has a consensus price target of $14.67, representing about 367.7% upside from its current price of $3.14.Amount of Analyst CoverageInventiva has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Inventiva's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Inventiva are expected to decrease in the coming year, from ($0.75) to ($0.85) per share. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.36% of the float of Inventiva has been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inventiva has recently increased by 26.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.85 News SentimentInventiva has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inventiva this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for IVA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Inventiva to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions19.06% of the stock of Inventiva is held by institutions.Read more about Inventiva's insider trading history. Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IVA Stock News HeadlinesInventiva faces crucial phase III test, Jefferies cuts price targetNovember 10, 2026 | marketscreener.comMHC Wainwright Comments on Inventiva FY2026 EarningsNovember 9, 2026 | americanbankingnews.comYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.November 20 at 1:00 AM | Reagan Gold Group (Ad)Jaipur court denies anticipatory bail to Inventiva publisher in extortionOctober 31, 2026 | msn.comInventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor’s Phase 3 Trial Unlock 62% Upside?October 28, 2026 | insidermonkey.comRajasthan Police file FIR against Inventiva publisher over alleged extortion of Terra Invest foundersOctober 20, 2026 | msn.comInventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease ReadoutOctober 14, 2026 | seekingalpha.comInventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026October 6, 2026 | finance.yahoo.comSee More Headlines IVA Stock Analysis - Frequently Asked Questions How have IVA shares performed this year? Inventiva's stock was trading at $4.65 at the beginning of 2026. Since then, IVA stock has decreased by 32.6% and is now trading at $3.1360. How were Inventiva's earnings last quarter? Inventiva S.A. Sponsored ADR (NASDAQ:IVA) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.15) EPS for the quarter. The business had revenue of $745.26 thousand for the quarter. When did Inventiva IPO? Inventiva (IVA) raised $108 million in an IPO on Friday, July 10th 2020. The company issued 7,478,261 shares at a price of $13.40-$15.40 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. Who are Inventiva's major shareholders? Top institutional shareholders of Inventiva include Aberdeen Group plc (1.32%), Nantahala Capital Management LLC (1.26%), Marshall Wace LLP (0.95%) and Integral Health Asset Management LLC (0.54%). How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inventiva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inventiva investors own include Larimar Therapeutics (LRMR), NVIDIA (NVDA), Ondas (ONDS), Advanced Micro Devices (AMD), Iovance Biotherapeutics (IOVA), Taysha Gene Therapies (TSHA) and Black Diamond Therapeutics (BDTX). Company Calendar Last Earnings9/28/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 IVA's financial health is in the Red zone, according to TradeSmith. IVA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IVA CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees77Year Founded2011Price Target and Rating Average Price Target for Inventiva$14.67 High Price Target$18.00 Low Price Target$12.00 Potential Upside/Downside+367.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.90 Current Ratio3.81 Quick RatioN/A Sales & Book Value Annual Sales$5.07 million Price / Sales147.92 Cash FlowN/A Price / Cash FlowN/A Book Value($0.22) per share Price / Book-14.25Miscellaneous Outstanding Shares239,150,000Free Float162,621,000Market Cap$749.97 million OptionableOptionable Beta0.76 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:IVA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.